EcoDrugPlus

Beta-2 Adrenergic Receptor

Ensembl ID : ENSCSEG00000012194
Gene Symbol: LOC103398145
3 Cross references
197 Possible Orthologues:

Beta-2 Adrenergic Receptor-Like

Ensembl ID : ENSCSEG00000019904
Gene Symbol: LOC103395540
2 Cross references
168 Possible Orthologues:

Beta-2 Adrenergic Receptor-Like

Ensembl ID : ENSCSEG00000019998
Gene Symbol: LOC103391399
3 Cross references
196 Possible Orthologues:

Beta-Secretase 1

Ensembl ID : ENSCSEG00000014707
Gene Symbol: BACE1
3 Cross references
221 Possible Orthologues:

Bradykinin Receptor B2

Ensembl ID : ENSCSEG00000004750
Gene Symbol: BDKRB2
4 Cross references
182 Possible Orthologues:

Breakpoint Cluster Region Protein

Ensembl ID : ENSCSEG00000010207
Gene Symbol: LOC103397445
3 Cross references
203 Possible Orthologues:

Calcium Channel, Voltage-Dependent, L Type, Alpha 1c Subunit

Ensembl ID : ENSCSEG00000009067
Gene Symbol: CACNA1C
1 Cross references
215 Possible Orthologues:

Calcium Channel, Voltage-Dependent, L Type, Alpha 1d Subunit, A

Ensembl ID : ENSCSEG00000001806
Gene Symbol: CACNA1DA
1 Cross references
212 Possible Orthologues:

Calcium Channel, Voltage-Dependent, L Type, Alpha 1f Subunit

Ensembl ID : ENSCSEG00000017631
Gene Symbol: CACNA1FB
1 Cross references
177 Possible Orthologues:

Calcium Channel, Voltage-Dependent, N Type, Alpha 1b Subunit, A

Ensembl ID : ENSCSEG00000008637
Gene Symbol: CACNA1BA
1 Cross references
211 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 7a

Ensembl ID : ENSCSEG00000016797
Gene Symbol: CACNG7A
2 Cross references
188 Possible Orthologues:

Calcium Sensing Receptor

Ensembl ID : ENSCSEG00000020372
Gene Symbol: CASR
3 Cross references
203 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).